Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants

Pediatric Infectious Disease Journal

Volumn 22, Issue 6, 2003, Pages 540-545

  Singleton, Rosalyn ^a,b   Dooley, Lea ^a   Bruden, Dana ^a   Raelson, Suzanne ^c   Butler, Jay C ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c SOUTHCENTRAL FOUNDATION   (United States)

Author keywords

Alaska Natives; Palivizumab; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; UNITED STATES; VIRUS INFECTION;

EID: 0038201665     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000069768.34383.18     Document Type: Article

References (30)

1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282:1440-6.
2. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22.
3. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks gestation. Pediatrics 1991;88:527-32.
4. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
5. MacDonald NE, Hall CB, Suffin SC, et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982;307:397-400.
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
7. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102:1211-16.
8. Meissner HC, Welliver RC, Chartrand SA, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatrics 1999;18:223-31.
9. Karron RA, Singleton R, Bulkow L, et al. Severe respiratory syncytial virus disease in Alaska Native children. J Infect Dis 1999;180:41-9.
10. Martine AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet 1978;2:1035-8.
11. Dagan R, Landau D, Haikin H, Tal A. Hospitalization of Jewish and Bedouin infants in southern Israel for bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J 1993;12:381-6.
12. Bulkow LR, Singleton RJ, Karron RA, Harrison LH. Risk factors for severe respiratory syncytial virus infection among Alaska Native children. Pediatrics 2002;109:210-12.
13. Breese Hall C, Stevens TP, Swantz RJ, Sinkin RA, Mcbride JT. Development of local guidelines for prevention of respiratory syncytial viral infection. Pediatr Infect Dis J 1999;18:850-3.
14. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillespy SR, Schutze GE. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch Pediatr Adolesc Med 1998;152:358-3.
15. Joffe S, Escobar G, Black S, Armstrong M, Lieu T. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
16. Moler F. Comments on palivizumab (commentary). Pediatrics 1999;104:495-6.
17. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27.
18. Sorrentino M, Powers T. Palivizumab Outcomes Study Group. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J 2000;9:1068-71.
19. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin Ther 1999;21:752-66.
20. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska Native children: causes and clinical courses. Pediatr Pulmonol 2000;29:182-7.
21. Lewis T. Prevalence of chronic respiratory symptoms among Alaska Native children. Master's thesis. Seattle, WA: University of Washington, 1999.
22. Singleton RJ, Bulkow L, Redding GJ, et al. Radiographic findings and risk factors for bronchiectasis among Alaska Native infants hospitalized with RSV as infants: 5 year follow-up [Board 91]. In: International Conference on Emerging Infectious Diseases, Atlanta, March 24 to 27, 2002. Atlanta: Centers for Disease Control, 2002.
23. Barker AF, Bardana EJ. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988;137:969-78.
24. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ. Bronchiectasis in Indigenous children in remote Australian communities. Med J Aust 2002;177:200-4.
25. Kolbe J, Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology 1996;1:221-5.
26. Seear M, Wensley D. Chronic cough and wheeze in children: do they all have asthma? Eur Respir J 1997;10:342-5.
27. Synagis (palivizumab): product monograph. Gaithersburg, MD: MedImmune, 2000.
28. Dudas R, Karron R. Respiratory syncytial virus vaccines. Clin Microbiol Rev 1998;11:430-9.
29. Piedra P. Respiratory syncytial virus vaccines: recent developments. Pediatr Infect Dis J 2000;19:805-8.
30. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000;182:1331-42.